---
title: 重庆兴泰濠制药有限公司 (Sintaho) vs Veranova
slug_a: sintaho
slug_b: veranova
site: cdmo
review_signal_gate: closed
canonical_path: /compare/sintaho/veranova
generated_by: BioBM Editorial AI
---

# 重庆兴泰濠制药有限公司 (Sintaho) vs Veranova

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

重庆兴泰濠制药有限公司 (Sintaho) (sintaho) is listed for cdmo. China-based API and CDMO/CMO supplier focused on cytotoxic and OEB5 high-potency APIs, peptides, and XDC compounds. Reports FDA on-site inspections in 2024 and 2025 and product registrations in more than 30 countries.

Services: 4. Modalities: 2. Indications: 0. Locations: 1. Certifications: 1. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (4).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

Veranova (veranova) is listed for cdmo. Global CDMO specializing in development and manufacturing of complex active pharmaceutical ingredients (APIs), with expertise in solid form sciences, process development, and specialty modalities including ADCs and controlled substances.

Services: 13. Modalities: 4. Indications: 0. Locations: 0. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (13).

Review summary: Review summary withheld until site-level review gate opens.